论文部分内容阅读
目的探讨阿托伐他汀与辛伐他汀治疗冠心病的临床疗效。方法选取南通市通州区第三人民医院2014年7月—2015年7月收治的82例冠心病患者,随机分为观察组与对照组,各41例。观察组患者给予阿托伐他汀治疗,对照组患者给予辛伐他汀治疗。比较两组患者治疗前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、尿素氮(BUN)、尿肌酐(Cr)、肌酸磷酸激酶(CPK)水平及不良反应发生情况。结果治疗前两组患者TC、TG、HDL-C、LDL-C水平比较,差异无统计学意义(P>0.05);治疗后观察组患者TG、LDL-C水平低于对照组,HDL-C水平高于对照组(P<0.05)。治疗后,两组患者TC比较,差异无统计学意义(P>0.05);两组患者TG、LDL-C水平低于治疗前,HDL-C水平高于治疗前(P<0.05)。两组患者治疗前后AST、ALT、BUN、Cr、CPK水平比较,差异无统计学意义(P>0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论辛伐他汀与阿托伐他汀治疗冠心病均具有较好的临床效果,但阿托伐他汀降脂效果更加明显,且未增加不良反应。
Objective To investigate the clinical efficacy of atorvastatin and simvastatin in the treatment of coronary heart disease. Methods 82 patients with coronary heart disease admitted from July 2014 to July 2015 in Tongzhou Third People’s Hospital of Nantong were randomly divided into observation group and control group, with 41 cases in each. Patients in the observation group were treated with atorvastatin and patients in the control group were given simvastatin. The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT) , Aspartate aminotransferase (AST), blood urea nitrogen (BUN), urinary creatinine (Cr), creatine phosphokinase (CPK) and the incidence of adverse reactions. Results There was no significant difference in the levels of TC, TG, HDL-C and LDL-C between the two groups before treatment (P> 0.05). The levels of TG and LDL-C in the observation group were lower than those in the control group The level was higher than the control group (P <0.05). After treatment, there was no significant difference in TC between the two groups (P> 0.05). The levels of TG and LDL-C in both groups were lower than those before treatment, and the levels of HDL-C were higher than those before treatment (P <0.05). There were no significant differences in the levels of AST, ALT, BUN, Cr and CPK between the two groups before and after treatment (P> 0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Both simvastatin and atorvastatin have a good clinical effect in the treatment of coronary heart disease. However, the lipid lowering effect of atorvastatin is more obvious with no adverse reactions.